01—Abstract
Summary
Summary of the 8-K filed May 7, 2026. Cited figures are marked; the original filing is the authoritative source.
STERIS plc (NYSE: STE) filed a Form 8-K reporting two board changes.
On May 1, 2026, Richard C. Breeden notified the Company that he will not stand for reelection at the 2026 Annual General Meeting of Shareholders. The Company stated that his decision is not the result of any disagreement on matters related to its operations, policies or practices.
He had served 18 years as a Director. On May 5, 2026, the Board increased its size from nine to ten members and appointed Pierre Boulud as a director, effective that date. Mr. Boulud, age 54, is CEO of bioMérieux, a biotechnology company focused on in vitro diagnostics, a role he has held since June 2023.
He will receive a prorated fee of $76,989a for the remainder of the Board's 2025-26 term, payable in career restricted stock units under the Non-Employee Director Compensation Program, and will be eligible for the same indemnification program as other Board members. The appointment was announced in a press release dated May 7, 2026, furnished as Exhibit 99.1 under Regulation FD. The Chairman, Mohsen Sohi, said Mr. Boulud's leadership experience, global perspective, strategic acumen and operational expertise make him an excellent addition to the Board.
02—Key points
Key Highlights
- Richard C. Breeden, a Director for 18 years, will not stand for reelection at the 2026 Annual General Meeting; the Company says the decision is not due to any disagreement.
- The Board expanded from nine to ten members on May 5, 2026, and appointed Pierre Boulud as a director effective that date.
- Mr. Boulud, age 54, has been CEO of bioMérieux since June 2023 and previously served as its COO from 2020, after joining in 2016.
- Mr. Boulud previously spent fourteen years at Ipsen, ending as Executive Vice President of Specialty Care Commercial Operations, and began his career at The Boston Consulting Group.
- Mr. Boulud receives a prorated fee of $76,989 for the rest of the 2025-26 term, payable in career restricted stock units under the Non-Employee Director Compensation Program.
- Mr. Boulud is eligible for the same indemnification program as other Board members.
- The appointment was announced in a May 7, 2026 press release (Exhibit 99.1), furnished under Item 7.01 and not deemed filed under Section 18 of the Exchange Act.
03—Questions
Frequently Asked Questions
Why is Richard C. Breeden leaving the Board?
Mr. Breeden notified the Company on May 1, 2026 that he will not stand for reelection at the 2026 Annual General Meeting. The filing states that his decision to retire is not the result of any disagreement with the Company on matters related to its operations, policies or practices.
Who is Pierre Boulud and what is his background?
Mr. Boulud, age 54, is CEO of bioMérieux, a biotechnology company focused on in vitro diagnostics, a role he has held since June 2023. He joined bioMérieux in 2016, became COO in 2020, and previously spent fourteen years at Ipsen, ending as Executive Vice President of Specialty Care Commercial Operations. He began his career at The Boston Consulting Group.
How is Mr. Boulud compensated for his Board service?
He will receive a prorated fee of $76,989 for the remainder of the Board's 2025-26 term. The fee is payable in career restricted stock units granted under the Company's Non-Employee Director Compensation Program.
How large is the Board after this change?
On May 5, 2026, the Board increased its size from nine to ten members and appointed Mr. Boulud to fill the new seat, effective that date.
Did the Company disclose any indemnification arrangements for the new director?
Yes. The filing states that Mr. Boulud will be eligible for the same indemnification program as the other members of the Board.
04—Continue